{"id":418500,"date":"2026-04-30T14:44:08","date_gmt":"2026-04-30T14:44:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/418500\/"},"modified":"2026-04-30T14:44:08","modified_gmt":"2026-04-30T14:44:08","slug":"20000-people-taking-drug-ricks-says","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/418500\/","title":{"rendered":"20,000 people taking drug, Ricks says"},"content":{"rendered":"<p><img decoding=\"async\" class=\"InlineVideo-videoThumbnail\" src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/04\/108299829-17775490031777548999-45610785768-1080pnbcnews.jpg\" alt=\"Eli Lilly CEO David Ricks on Q1 results, Zepbound-Mounjaro sales growth and launch of Foundayo pill\"\/><\/p>\n<p>More than 20,000 people have started taking <a href=\"https:\/\/www.cnbc.com\/quotes\/LLY\/\" rel=\"nofollow noopener\" target=\"_blank\">Eli Lilly<\/a>&#8216;s GLP-1 pill Foundayo in its first few weeks on the market, Lilly CEO Dave Ricks told CNBC on Thursday. <\/p>\n<p>The FDA approved Lilly&#8217;s once-daily pill Foundayo earlier this month, making it the second oral GLP-1 drug behind Novo Nordisk&#8217;s Wegovy pill. Investors have been closely tracking weekly prescriptions for clues on how the launch is going. <\/p>\n<p>More than 1,000 people are starting Foundayo a day, Ricks said in an exclusive interview with CNBC. He said it&#8217;ll take time to build the brand since it&#8217;s a new drug that doctors and patients don&#8217;t know. He contrasted it against the launch of the company&#8217;s Zepbound weight loss injection, which had the same active ingredient as its existing diabetes drug, Mounjaro, and against Novo&#8217;s Wegovy pill, which had the same brand name and active ingredient as the shot. <\/p>\n<p>&#8220;So what we&#8217;re seeing now is basically organic demand, which is pretty strong to us,&#8221; Ricks said. <\/p>\n<p>&#8220;This is going to play out over quarters, not days, and I just ask people to take a beat and let us execute,&#8221; Ricks said. &#8220;I think it&#8217;s going to be just fine.&#8221;<\/p>\n<p>More than 80% of people taking Foundayo are new to GLP-1s, he said.<\/p>\n<p>Ricks spoke to CNBC after Eli Lilly <a href=\"https:\/\/www.cnbc.com\/2026\/04\/30\/eli-lilly-lly-earnings-q1-2026.html\" rel=\"nofollow noopener\" target=\"_blank\">posted first-quarter earnings and revenue<\/a> that easily beat expectations. Due to the timing of the launch, Foundayo was not included in the results. <\/p>\n<p>During the quarter, sales of Mounjaro and Zepbound spiked 125% and 80%, respectively. <\/p>\n<p>Eli Lilly is trying to maintain its dominance in the GLP-1 market following the successful launch of Novo Nordisk&#8217;s oral drug. It held a 60.1% share of the U.S. obesity and diabetes drug market in the first quarter, versus 39.4% for Novo Nordisk, according to an earnings presentation.<\/p>\n<p><a href=\"https:\/\/www.google.com\/preferences\/source?q=https:\/\/www.cnbc.com\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"More than 20,000 people have started taking Eli Lilly&#8216;s GLP-1 pill Foundayo in its first few weeks on&hellip;\n","protected":false},"author":2,"featured_media":367965,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[2580,357,2576,163,2579,521,85,46,2577],"class_list":["post-418500","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-biotech-and-pharmaceuticals","tag-business-news","tag-eli-lilly-and-co","tag-health","tag-health-care-industry","tag-healthcare","tag-il","tag-israel","tag-novo-nordisk-a-s"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/418500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=418500"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/418500\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/367965"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=418500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=418500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=418500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}